234 related articles for article (PubMed ID: 26067721)
1. Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis.
Artigalás O; Vanni T; Hutz MH; Ashton-Prolla P; Schwartz IV
BMC Med; 2015 Jun; 13():139. PubMed ID: 26067721
[TBL] [Abstract][Full Text] [Related]
2. Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial.
Fontein DB; Houtsma D; Nortier JW; Baak-Pablo RF; Kranenbarg EM; van der Straaten TR; Putter H; Seynaeve C; Gelderblom H; van de Velde CJ; Guchelaar HJ
Breast Cancer Res Treat; 2014 Apr; 144(3):599-606. PubMed ID: 24590773
[TBL] [Abstract][Full Text] [Related]
3. CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
Leyland-Jones B; Gray KP; Abramovitz M; Bouzyk M; Young B; Long B; Kammler R; Dell'Orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Harvey VJ; Neven P; Treilleux I; Rasmussen BB; Maibach R; Price KN; Coates AS; Goldhirsch A; Pagani O; Viale G; Rae JM; Regan MM
Breast Cancer Res Treat; 2015 Jun; 151(2):373-84. PubMed ID: 25935582
[TBL] [Abstract][Full Text] [Related]
4. Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.
Umamaheswaran G; Kadambari D; Muthuvel SK; Kalaivani S; Devi J; Damodaran SE; Pradhan SC; Dubashi B; Dkhar SA; Adithan C
Breast Cancer Res Treat; 2020 Jul; 182(1):147-158. PubMed ID: 32385792
[TBL] [Abstract][Full Text] [Related]
5. CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients.
Simonsson M; Veerla S; Markkula A; Rose C; Ingvar C; Jernström H
BMC Cancer; 2016 Mar; 16():256. PubMed ID: 27029552
[TBL] [Abstract][Full Text] [Related]
6. Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial.
Johansson H; Gray KP; Pagani O; Regan MM; Viale G; Aristarco V; Macis D; Puccio A; Roux S; Maibach R; Colleoni M; Rabaglio M; Price KN; Coates AS; Gelber RD; Goldhirsch A; Kammler R; Bonanni B; Walley BA;
Breast Cancer Res; 2016 Nov; 18(1):110. PubMed ID: 27825388
[TBL] [Abstract][Full Text] [Related]
7. Research on aromatase gene (CYP19A1) polymorphisms as a predictor of endocrine therapy effectiveness in breast cancer.
Miron L; Negură L; Peptanariu D; Marinca M
Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):997-1004. PubMed ID: 23700878
[TBL] [Abstract][Full Text] [Related]
8. A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma.
Colomer R; Monzo M; Tusquets I; Rifa J; Baena JM; Barnadas A; Calvo L; Carabantes F; Crespo C; Muñoz M; Llombart A; Plazaola A; Artells R; Gilabert M; Lloveras B; Alba E
Clin Cancer Res; 2008 Feb; 14(3):811-6. PubMed ID: 18245543
[TBL] [Abstract][Full Text] [Related]
9. S4646 polymorphism in CYP19A1 gene is associated with the efficacy of hormone therapy in early breast cancer.
Shao X; Cai J; Zheng Y; Wang J; Feng J; Huang Y; Shi L; Chen Z; Guo Y; Wang X
Int J Clin Exp Pathol; 2015; 8(5):5309-17. PubMed ID: 26191232
[TBL] [Abstract][Full Text] [Related]
10. Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole.
Lunardi G; Piccioli P; Bruzzi P; Notaro R; Lastraioli S; Serra M; Marroni P; Bighin C; Mansutti M; Puglisi F; Porpiglia M; Ponzone R; Bisagni G; Garrone O; Cavazzini G; Clavarezza M; Del Mastro L
Breast Cancer Res Treat; 2013 Jan; 137(1):167-74. PubMed ID: 23129173
[TBL] [Abstract][Full Text] [Related]
11. Association between rs10046, rs1143704, rs767199, rs727479, rs1065778, rs1062033, rs1008805, and rs700519 polymorphisms in aromatase (CYP19A1) gene and Alzheimer's disease risk: a systematic review and meta-analysis involving 11,051 subjects.
Song Y; Lu Y; Liang Z; Yang Y; Liu X
Neurol Sci; 2019 Dec; 40(12):2515-2527. PubMed ID: 31278540
[TBL] [Abstract][Full Text] [Related]
12. CYP19A1 rs10046 Pharmacogenetics in Postmenopausal Breast Cancer Patients Treated with Aromatase Inhibitors: One-year Follow-up.
Baatjes K; Peeters A; McCaul M; Conradie MM; Apffelstaedt J; Conradie M; Kotze MJ
Curr Pharm Des; 2020; 26(46):6007-6012. PubMed ID: 32900345
[TBL] [Abstract][Full Text] [Related]
13. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients.
Fasching PA; Loehberg CR; Strissel PL; Lux MP; Bani MR; Schrauder M; Geiler S; Ringleff K; Oeser S; Weihbrecht S; Schulz-Wendtland R; Hartmann A; Beckmann MW; Strick R
Breast Cancer Res Treat; 2008 Nov; 112(1):89-98. PubMed ID: 18049890
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients.
Ferraldeschi R; Arnedos M; Hadfield KD; A'Hern R; Drury S; Wardley A; Howell A; Evans DG; Roberts SA; Smith I; Newman WG; Dowsett M
Breast Cancer Res Treat; 2012 Jun; 133(3):1191-8. PubMed ID: 22418701
[TBL] [Abstract][Full Text] [Related]
15. Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer.
Park IH; Lee YS; Lee KS; Kim SY; Hong SH; Jeong J; Lee H; Ro J; Nam BH
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1263-71. PubMed ID: 21442439
[TBL] [Abstract][Full Text] [Related]
16. Haplotype structures and functional polymorphic variants of the drug target enzyme aromatase (CYP19A1) in South Indian population.
Umamaheswaran G; Dkhar SA; Kalaivani S; Anjana R; Revathy M; Jaharamma M; Shree KM; Kadambari D; Adithan C
Med Oncol; 2013; 30(3):665. PubMed ID: 23893151
[TBL] [Abstract][Full Text] [Related]
17. A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole.
Garcia-Casado Z; Guerrero-Zotano A; Llombart-Cussac A; Calatrava A; Fernandez-Serra A; Ruiz-Simon A; Gavila J; Climent MA; Almenar S; Cervera-Deval J; Campos J; Albaladejo CV; Llombart-Bosch A; Guillem V; Lopez-Guerrero JA
BMC Cancer; 2010 Feb; 10():36. PubMed ID: 20144226
[TBL] [Abstract][Full Text] [Related]
18. Predictive markers in elderly patients with estrogen receptor-positive breast cancer treated with aromatase inhibitors: an array-based pharmacogenetic study.
Rumiato E; Brunello A; Ahcene-Djaballah S; Borgato L; Gusella M; Menon D; Pasini F; Amadori A; Saggioro D; Zagonel V
Pharmacogenomics J; 2016 Nov; 16(6):525-529. PubMed ID: 26503812
[TBL] [Abstract][Full Text] [Related]
19. Alcohol-related breast cancer in postmenopausal women - effect of CYP19A1, PPARG and PPARGC1A polymorphisms on female sex-hormone levels and interaction with alcohol consumption and NSAID usage in a nested case-control study and a randomised controlled trial.
Kopp TI; Jensen DM; Ravn-Haren G; Cohen A; Sommer HM; Dragsted LO; Tjonneland A; Hougaard DM; Vogel U
BMC Cancer; 2016 Apr; 16():283. PubMed ID: 27102200
[TBL] [Abstract][Full Text] [Related]
20. SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials.
Conte B; Boni L; Bisagni G; Durando A; Sanna G; Gori S; Garrone O; Tamberi S; De Placido S; Schettini F; Pazzola A; Ponzone R; Montemurro F; Lunardi G; Notaro R; De Angioletti M; Turletti A; Mansutti M; Puglisi F; Frassoldati A; Porpiglia M; Fabi A; Generali D; Scognamiglio G; Rossi M; Brasó-Maristany F; Prat A; Cardinali B; Piccioli P; Serra M; Lastraioli S; Bighin C; Poggio F; Lambertini M; Del Mastro L
Clin Cancer Res; 2023 Dec; 29(24):5217-5226. PubMed ID: 37888299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]